Thomas File
Infectious Disease · Akron, OHNPI 1366529091
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Merck at 33.9% of the total. 2025 is the largest year on record at $31,562, 5.6 times the $5,666 reported in 2019. Among infectious disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $302.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$23K
- Shionogi Inc$19K
- Fisher Scientific Company L.L.C.$9K
- Paratek Pharmaceuticals, Inc.$7K
- Pfizer$4K
- Nabriva Therapeutics, PLC$3K
- plus $4K from 16 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
What the payments were for
- Consulting fees$32,96448%
- Speaking & faculty fees$13,81120%
- Travel & lodging$15,70823%
- Food & beverage$5,9149%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 41 | $23,187 |
| Shionogi Inc | 9 | $18,560 |
| Fisher Scientific Company L.L.C. | 13 | $8,944 |
| Paratek Pharmaceuticals, Inc. | 7 | $7,048 |
| Pfizer | 2 | $3,621 |
| Nabriva Therapeutics, PLC | 2 | $3,337 |
| Gilead | 63 | $1,569 |
| Johnson & Johnson | 30 | $621 |
| Insmed, Inc. | 6 | $347 |
| Viiv Healthcare Company | 22 | $306 |
| Janssen Products, LP | 3 | $268 |
| Oyster Point Pharma, Inc. | 2 | $206 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $112 |
| AbbVie(2 entities) | 5 | $68 |
| Astellas Pharma US Inc | 3 | $55 |
| Cumberland Pharmaceuticals, Inc. | 3 | $49 |
| Theratechnologies Inc. | 3 | $42 |
| Melinta Therapeutics, LLC | 2 | $41 |
| Aimmune Therapeutics, Inc. | 1 | $31 |
| Napo Pharmaceuticals Inc | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Vyera Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fetroja$15,804
- CAPVAXIVE$10,342
- NUZYRA$6,916
- Procalcitonin$5,737
- PREVNAR 20$3,621
- Xenleta$3,300
- BRAHMS PCT KRYPTOR$2,997
- S-217622$2,575
- PNEUMOVAX 23$1,057
- Arikayce$254
- Biktarvy$240
- Symtuza$237
- Sunlenca$108
- TYRVAYA$108
How this compares
$68,457 in reported general payments places this provider in the 95th percentile of 308 infectious disease providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 17 | $64,784 |
| TivicayDolutegravir Sodium | 21 | $43,779 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $27,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,569 | $92,12630 claims |
| Viiv Healthcare CompanyTivicay | $306 | $43,77921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 infectious disease providers in Ohio.
Other infectious disease in Akron
- Michael TanAkron$26K
- Anthony LeungAkron$3K
- Aimee MandapatAkron$3K
- Steven BurdetteDayton$322K
- Nathaniel RatnasamyFindlay$255K
- Melissa JenkinsCleveland$127K
- Grace McComseyCleveland$123K
- Steven GordonCleveland$78K
- Nicholas CongerWright Patterson Afb$76K
- Alan TaegeCleveland$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.